Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Common Stock Issued

Cash raised by issuing new shares.

Maze Therapeutics, Inc.NASDAQ: MAZE

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued declines year over year

Q1 FY2026 common stock issued of $3.84M fell 97.0% year over year, ahead of the -160.7% change in trailing-twelve-month common stock issued. Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at +442.5% a year.

Context

  • Common stock issued increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -97.0% holds above the trailing-twelve-month pace of -160.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.84M+7.0% QoQ
Last fiscal yearDec 2025
$275.84M+303.4% YoY
LTMMar 2026
-$120.32M-160.7% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.0%——
1 year+303.4%——
3-year CAGR+442.5%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
275.84M USD
Year-over-year change
+303.4%
3-year CAGR
+442.5%

Common Stock Issued vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -160.7% is the lowest of 7, against a peer median of +87.2%.
  • Common stock issued amounts to 601.6% of revenue for MAZE, versus a peer median of 7.2%.
MAZE Competitors
Common Stock Issued for MAZE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€237.74M EUR+314.6%+199.8%5303.2%
BIOABioAge Labs, Inc.LTM Mar 2026$143.89M USD+420.9%+640.5%1394.8%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$120.32M USD-160.7%+442.5%601.6%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$102.13M USD+121.2%+25.6%10.1%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$44.53M USD———
TVTXTravere Therapeutics, Inc.LTM Sep 2026$27.2M USD-81.2%+24.3%4.2%
ARDXArdelyx, Inc.LTM Mar 2026$9.8M USD+53.2%-56.6%2.3%
SEPNSepterna, Inc.LTM Sep 2026$1.02M USD-99.7%+174.2%1.1%
Peer median (excluding MAZE) —+87.2%+99.9%7.2%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(114.94M)(100.42M)52.23M(131.12M)
Depreciation & Amortization3.82M4.09M3.3M2.4M
Deferred Income Tax0000
Stock-Based Compensation6.74M8.75M9.65M16.4M
Change in Working Capital(3.24M)(6.32M)(1.52M)(2.27M)
Accounts Receivables0000
Inventory0000
Accounts Payables(3.78M)399K(204K)(27K)
Other Working Capital541K(6.72M)(1.32M)(2.25M)
Other Non-Cash Items8.42M7.07M12.3M2.65M
Operating Cash Flow(99.2M)(86.83M)75.95M(111.94M)
Capital Expenditures(1.97M)(441K)(1.15M)(794K)
Acquisitions (Net)(1.2M)000
Purchases of Investments000(187.67M)
Sales of Investments00017.5M
Other Investing Activities0000
Investing Cash Flow(3.17M)(441K)(1.15M)(170.96M)
Debt Repayment016.18M24.48M0
Common Stock Issued1.73M209K68.37M275.84M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities000(500K)
Financing Cash Flow1.73M16.39M92.85M275.34M
Effect of Forex Changes0000
Net Change in Cash(100.65M)(70.88M)167.65M(7.57M)
Free Cash Flow(101.17M)(87.27M)74.81M(112.73M)

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.